You are here: Industry Insights > Pacritinib

News List

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis drugs
June 21, 2021
CTI BioPharma Corp.today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet counts less than 50 x 109/L)
Combining pacritinib with sirolimus-based GvHD prophylaxis may improve efficacy europeanpharmaceuticalreview
March 25, 2021
Phase I results suggest adding pacritinib to sirolimus and low-dose tacrolimus could be beneficial in preventing graft-versus-host disease (GvHD).
CTI Biopharma Announces Phase 3 Pacritinib for COVID-19 Hospitalized Patients americanpharmaceuticalreview
April 30, 2020
CTI BioPharma announced the initiation of PRE-VENT, a Phase 3 study evaluating pacritinib in hospitalized patients with severe COVID-19.
CTI BioPharma Initiates Phase III Pacritinib Trial in COVID-19 contractpharma
April 28, 2020
Will compare pacritinib plus standard of care versus placebo plus standard of care in 358 patients with severe COVID-19.
CTI BioPharma Completes Enrollment of Phase 2 PAC203 Study of Pacritinib americanpharmaceuticalreview
December 29, 2018
CTI BioPharma announced the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of pacritinib. The company expects to report the determination of ......
CTI BioPharma Corp. Restructures contractpharma
December 17, 2018
CTI BioPharma Corp. is restructuring in an effort to improve efficiencies and reduce costs. As part of the plan, workforce reductions have been implemented that impact approximately 50 percent
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology biospace
March 12, 2018
CTI Biopharma Corp.today announced that results from the Phase 3 PERSIST-2 clinical trial of pacritinib (an investigational JAK2 inhibitor) have been published online in JAMA Oncology.